Healthcare Sector Roundup: Hologic (NASDAQ:HOLX), Insulet (NASDAQ:PODD) – HOLX, PODD, JNJ, AVEO, CYTK, GALE

Investors responded negatively to the healthcare stocks on Monday. Key movement were observed in AVEO Pharmaceuticals, Inc (NASDAQ:AVEO) and Cytokinetics, Inc (NASDAQ:CYTK) on percentage gainers side while Galena Biopharma Inc (NASDAQ:GALE) was prominent stock on percentage gainer side.

Hologic, Inc (NASDAQ:HOLX) announced fiscal Q2 earnings loss widened amid acquisition-related costs and special items as the company declared strong revenue growth.

The health-care products company shattered its EPS outlook in the range of $1.54 to $1.56 per for the year on revenue of $2.53 billion to $2.55 billion.

Hologic posted a loss of $51.1 million or 19 cents per share for three months period finished March 30, contrasted against a loss of $40.3 million or 15 cents per share in previous year.

Hologic, Inc.’s YTD performance was recorded as 267.70% while its market capitalization was $5.53 billion. The company has P/B ratio of 1.85. Institutional ownership owns 96.84% shares of the company while beta factor, which is used to measure riskiness of the security, was 1.18. Net profit margin of the company was -4.23% while its gross profit margin was 48.40%.

Insulet Corporation (NASDAQ:PODD) revealed a loss for fiscal Q1 that narrowed from previous year on higher revenues, showing strong demand for the new Omnipod insulin pump following its launch in February.
Medical device company loss was also narrower than Wall Street forecasts, while revenues top their outlook.

Insulet Corporation has market capitalization of $1.32 billion. Its current ratio was 2.28 while its shares were looking forward SMA50 with 0.55. The company offered earnings per share of -1.08 while its 53.29 million shares were outstanding. YTD performance of the stock was 17.20%.

Johnson & Johnson (NYSE:JNJ) has the market capitalization of $230.70 billion. The company’s EPS was 3.67 while its 2.80 billion shares were outstanding. Its institutional ownership was 68.30%. Shares of the company were moving ahead of SMA50 with 4.63% while its YTD performance was 21.77%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , , , , , , , . Bookmark the permalink.